Stockholm3 Detected More Significant Prostate Cancers Than PSA - Report - MDSpire

Stockholm3 Detected More Significant Prostate Cancers Than PSA

In a Swedish population-based screening cohort, the blood-based risk model had higher short-term sensitivity for clinically significant prostate cancer than prostate-specific antigen testing, with similar specificity.

  • By

  • Andrea Surnit

  • June 25, 2026

  • 5 min

Share

Clinical Report: Stockholm3 Detected More Significant Prostate Cancers Than PSA

Overview

The Stockholm3 screening test identified more clinically significant prostate cancers than traditional prostate-specific antigen (PSA) testing within a 2-year follow-up period. This secondary analysis of the STHLM3-MRI trial involved 12,670 men and demonstrated that Stockholm3 had a sensitivity of 90% compared to 74% for PSA.

Background

Prostate cancer screening is crucial for early detection and treatment, particularly for clinically significant cancers. Traditional PSA testing has limitations, including lower sensitivity and higher false-negative rates. The introduction of the Stockholm3 test, which combines PSA with additional biomarkers and clinical factors, aims to improve detection rates.

Data Highlights

Screening MethodSensitivityFalse-Negative RateSpecificityFalse-Positive Rate
Stockholm390%10%89%11%
PSA74%26%90%10%

Key Findings

  • Stockholm3 detected 400 clinically significant prostate cancers, while PSA detected 327.
  • Stockholm3 had a sensitivity of 90% compared to 74% for PSA.
  • Stockholm3 missed 43 clinically significant cancers, whereas PSA missed 116.
  • Specificity was similar between both tests, at 89% for Stockholm3 and 90% for PSA.
  • Per 1,000 men screened, Stockholm3 detected approximately 32 significant cancers compared to 26 by PSA.
  • Decision curve analysis indicated greater clinical net benefit for Stockholm3 across biopsy decision thresholds.

Clinical Implications

The findings suggest that integrating the Stockholm3 test into prostate cancer screening protocols may enhance the detection of clinically significant cancers while maintaining similar specificity to PSA testing. This could lead to more informed decision-making regarding biopsy referrals.

Conclusion

The Stockholm3 test demonstrates superior sensitivity in detecting clinically significant prostate cancers compared to traditional PSA testing.

Related Resources & Content

  1. the pathologist, The Pathologist, 2026 -- Stockholm3 Test Cuts MRIs in Prostate Screening
  2. The ASCO Post, The ASCO Post, 2014 -- PSA—It Just Keeps Getting Better, So Why Should It Stand Alone?
  3. The ASCO Post, The ASCO Post, 2026 -- Studies Suggest Prostate Cancer Screening May Be Equivalent to Breast Cancer Screening in Key Outcomes
  4. Final Recommendation Statement: Screening for Prostate Cancer | United States Preventive Services Taskforce
  5. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial - ScienceDirect
  6. Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial - PubMed
  7. The ASCO Post — Studies Suggest Prostate Cancer Screening May Be Equivalent to Breast Cancer Screening in Key Outcomes
  8. Final Recommendation Statement: Screening for Prostate Cancer | United States Preventive Services Taskforce
  9. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial - ScienceDirect
  10. Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial - PubMed

Original Source(s)

Stockholm3 Detected More Significant Prostate Cancers Than PSA

  • by Andrea Surnit

  • June 25, 2026

Related Content

Lactate Biomarker May Predict Outcomes in Cardiogenic Shock

A review of cardiogenic shock studies suggests serial lactate measurements provide more prognostic information than isolated values and may better reflect treatment response.

Top 10 States for Early-Career Physicians

These 10 states reported physician residency completion totals, physician retention rates, or residency Match fill rates identified in graduate medical education data.

Language Barriers Linked to Cancer Treatment Delays

Texas registry data point to neighborhood-level vulnerability as a possible target for improving timely colorectal cancer care.